Login to Your Account



GSK's Witty Calls Out Pricing as a Threat to EU Innovation

By Nuala Moran
Staff Writer

Wednesday, June 27, 2012

LONDON – Andrew Witty, CEO of GlaxoSmithKline plc and president of the European Federation of Pharmaceutical Industries and Associations (EFPIA), hit out at austerity-driven pricing and reimbursement policies in an open letter to European heads of state delivered on Monday.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription